Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC)

Mycoses

Volumn 56, Issue 5, 2013, Pages 532-542

  Neoh, Chin Fen ^a,b   Liew, Danny ^c   Slavin, Monica A ^d   Marriott, Debbie ^e   Chen, Sharon C A ^f   Morrissey, Orla ^a   Stewart, Kay ^a   Kong, David C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b University of Technology Mara Penang   (Malaysia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

Author keywords

Candida spp.; Cost; Economic; Liposomal amphotericin B; Micafungin; Modelling

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDEMIA; CANDIDIASIS; COST; DEATH; DRUG COST; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; HOSPITAL; HOSPITALIZATION COST; HUMAN; INFUSION RELATED REACTION; INVASIVE CANDIDIASIS; LENGTH OF STAY; LIVER TOXICITY; MONTE CARLO METHOD; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

CANDIDA SPP.; COST; ECONOMIC; LIPOSOMAL AMPHOTERICIN B; MICAFUNGIN; MODELLING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AUSTRALIA; CANDIDEMIA; CANDIDIASIS, INVASIVE; ECHINOCANDINS; HEALTH CARE COSTS; HUMANS; LIPOPEPTIDES; TREATMENT OUTCOME;

CANDIDA;

EID: 84881030089     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12071     Document Type: Article

References (34)

1. Thursky KA, Playford EG, Seymour JF et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008; 38: 496-520.
2. Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth WC. Burden of hospitalisation of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis 2004; 8: 111-20.
3. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
4. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidaemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
5. Sobel JD, Revankar SG. Echinocandins-first-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007; 356: 2525-6.
6. Kuse E-R, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. The Lancet 2007; 369: 1519-27.
7. Cornely OA, Sidhu M, Odeyemi I, van Engen AK, van der Waal JM, Schoeman O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008; 24: 1743-53.
8. Park G, Sidhu M, Van Engen AK et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in the United Kingdom. In: (Ed), Abstracts of the 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcome Research, Toronto, Canada, 2008. Gwinnett: Abstract PIN27, International Society for Pharmacoeconomics and Outcome Research (ISPOR).
9. Viale P, Sidhu M, van Engen A et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Italy. In: (Ed), Abstracts of the 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcome Research, Athens, Greece, 2008. Gwinnett: Abstract PIN13, International Society for Pharmacoeconomics and Outcome Research (ISPOR).
10. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia Australia. Emerg Infect Dis 2006; 12: 1508-16.
11. Hawser S, Islam K. Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Candida albicans. J Antimicrob Chemother 1999; 43: 411-3.
12. Marriott DJ, Playford EG, Chen S et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009; 13: R115.
13. Worth LJ, Blyth CC, Booth DL et al. Optimising antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern Med J 2008; 38: 521-37.
14. Australian Bureau of Statistics. National Health Survey:Summary of Results (2005). http://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/3B1917236618A042CA25711F00185526/$File/43640_2004-05.pdf (accessed on 1 August 2010).
15. Australian Bureau of Statistics. Consumer Price Index (2010). http://www.ausstats.abs.gov.au/ausstats/meisubs.nsf/0/DB27E14A103FB951CA25776D001B5ADF/$File/64010_jun%202010.pdf (accessed on 1 August 2010).
16. Australian Government of Health and Ageing. National Hospital Cost Data Collection. Round 13 (2008-09) Cost Report Version 5.2 http://www.health.gov.au/internet/main/publishing.nsf/Content/EB1A34EB4E8208ECCA25773B00031A09/$File/HeaderR13CWNatEst.pdf (accessed on 1 August 2010).
17. Rechner IJ, Lipman J. The costs of caring for patients in a tertiary referral Australian intensive care unit. Anaesth Intensive Care 2005; 33: 477-82.
18. Australian Government of Health and Ageing. Medicare Benefits Schedule Book (2010). http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/BBE433BF3FE34A39CA257735001236D4/$File/201007-MBS.pdf (1 August 2010, date last accessed).
19. Health Purchasing Victoria. Health Purchasing Victoria Tender (2010-2012). http://www.hpv.org.au/ (3 November 2010, date last accessed).
20. Organisation for Economic Co-operation and Development (OECD). Pharmaceutical Pricing Policies in a Global Market. Paris, France: OECD Publishing, 2008.
21. Pappas PG, Rotstein CMF, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
22. O'Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. Health Econ 2007; 16: 1009-23.
23. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chemother 2009; 63: 197-208.
24. Collins CD, Stuntebeck ER, DePestel DD, Stevenson JG. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia. Clin Drug Investig 2007; 27: 233-41.
25. Dixon S, McKeen E, Tabberer M, Paisley S. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. PharmacoEconomics 2004; 22: 421-33.
26. Johnson MD, Kleinberg M, Danziger L, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy: challenges and future directions. Expert Opin Pharmacother 2005; 6: 2617-32.
27. Bruynesteyn K, Gant V, McKenzie C et al. A cost-effectiveness analysis of caspofungin versus liposomal amphotericin B for treatment of suspected fungal infections in the United Kingdom. Eur J Haematol 2007; 78: 532-9.
28. Gagne JJ, Goldfarb NI. Candidemia in the in-patient setting: treatment options and economics. Expert Opin Pharmacother 2007; 8: 1643-50.
29. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York: Oxford University Press, 2000.
30. Gold M, Seigel J, Russell L, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
31. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics 2006; 24: 355-71.
32. Sullivan W, Payne K. The appropriate elicitation of expert opinion in economic models: making expert data fit for purpose. PharmacoEconomics 2011; 29: 455-9.
33. Al-Badriyeh D, Liew D, Stewart K, Kong DC. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. J Antimicrob Chemother 2009; 63: 1276-85.
34. Wenzel R, Del Favero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005; 55: 352-61.